GTS Securities LLC Buys New Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

GTS Securities LLC bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 97,558 shares of the company's stock, valued at approximately $1,292,000.

A number of other hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $52,000. Cromwell Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $61,000. Venturi Wealth Management LLC lifted its holdings in shares of Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded up $0.20 during trading on Thursday, hitting $14.79. 2,503,202 shares of the stock were exchanged, compared to its average volume of 1,932,662. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The company's fifty day simple moving average is $14.66 and its 200-day simple moving average is $14.03. The company has a market capitalization of $47.06 billion, a price-to-earnings ratio of 36.98, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.